Category Archives: AZBio News

Dr. Michelle McMurry-Heath will become BIO’s President and CEO on June 1, 2020

Posted on by

After a comprehensive search, the Biotechnology Innovation Organization (BIO) has announced that Michelle McMurry-Heath, MD, PhD, as its incoming President and CEO.  McMurry-Heath will become the organization’s next President and CEO on June 1, 2020. 

BIO is the world’s largest science and public advocacy organization, representing 1,000 members.  McMurry-Heath will succeed former Rep. Jim Greenwood, who has led the organization since 2005 and BIO’s founding President & CEO Carl B. Feldbaum who served from 1993 to  2004.Continue reading→

C-Path and Provention Bio Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes

Posted on by

 

TUCSON, Ariz., and OLDWICK, N.J. May 13, 2020 — The Critical Path Institute (C-Path) and Provention Bio, Inc. (Nasdaq: PRVB) are proud to announce their collaboration to significantly improve the scientific community’s insight into type 1 diabetes (T1D) through Provention’s contribution of data from the Phase III Protégé study of teplizumab to the T1D Trial Outcome Measures Initiative (TOMI) integrated database. The Protégé study evaluated teplizumab on the preservation of beta cell function in newly onset T1D patients and generated the largest disease modifying interventional clinical trial dataset in T1D with more than 500 patients.Continue reading→

Biotechnology Innovation Organization Launches New Medicine Pipeline Tracker Illustrates Unprecedented Effort to Eradicate COVID-19

Posted on by

Washington, DC (May 12, 2020) – The Biotechnology Innovation Organization (BIO) today unveiled a first-of-its-kind, interactive tracker of the new treatments and vaccines in the COVID-19 pipeline. This online resource illustrates the unprecedented campaign being undertaken by biopharmaceutical innovators to combat – and ultimately eradicate – the novel coronavirus. Continue reading→

AdvaMed Issues MedTech Compliance Guidance For COVID-19 Response

Posted on by

WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced availability of a newly created “Code of Ethics Compliance Guidance Related to the COVID-19 Response.”

“This guidance seeks to help AdvaMed members and other medical technology companies develop and implement processes that both support rapid decision-making in the context of the pandemic and mitigate any related compliance risks,” said Christopher L. White, AdvaMed COVID action team leader, chief operating officer and general counsel.Continue reading→

What is the Bipartisan Commission on Biodefense?

Posted on by

On January 20, 2019,  AZBio hosted a thought leadership event at Barrett-Jackson Scottsdale featuring a panel discussion on Health Innovation with Dr. Anna Barker and Dr. George Poste.   During the discussion, Dr. Poste, shared his thoughts on the need for governments and our industry to prepare for global pandemics and what the Bipartisan Commission on Biodefense had reported. Dr. Poste, an ex officio member of the commission, shared that is was not a matter of if a global pandemic would occur, but of when. 

The first report of a COVID-19 case in the U.S. was January 20, 2020.  Today, the world is learning more about what happens in a global pandemic than we ever wanted to know.  And, we still have a lot more to learn.Continue reading→

Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens

Posted on by

The authorization is limited to testing performed at the Rutgers Clinical Genomics Laboratory using their molecular LDT COVID-19 authorized test for saliva specimens collected using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.  FDA states “It is important to note that this is not a general authorization for at-home collection of patient samples using other collection methods, saliva collection devices, or tests, or for tests fully conducted at home.”

Continue reading→